Paragraph IV Patent Certifications
October 21, 2014
The PDF contains a list of drug products for which an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification. This list includes the name of the drug product, dosage form, strength (subject of Paragraph IV certification), reference listed drug (RLD), and the date on which the first substantially complete generic drug application was submitted to the Agency (on a prospective basis beginning 3/2/2004). The Agency will not disclose the identity of the applicant. This information will be updated twice a month and will be as current as the last update. This information should be used for reference only. The Agency will make every effort to ensure the accuracy of the information disclosed in this list. However, any discrepancies or disparities should be discussed with the Regulatory Support Branch at 240-276-8400, before making any decisions based on this information.
|DRUG NAME||DOSAGE FORM||STRENGTH||RLD||DATE OF SUBMISSION|
|Azelastine Hydrochloride and Fluticasone Propionate||Nasal Spray||137 mcg/50 mcg per spray||Dymista||6/13/2014|
|Exenatide||Injection||250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe||Byetta||6/11/2014|
|Ribavirin||For Inhalation Solution||6 gm/vial||Virazole||5/22/2014|
|Topiramate||Extended-release Capsules||25 mg, 50 mg, and 100 mg||Trokendi XR||5/12/2014|